4.8 Article

Tetrahedral-Framework Nucleic Acids Carry Small Interfering RNA to Downregulate Toll-Like Receptor 2 Gene Expression for the Treatment of Sepsis

Journal

ACS APPLIED MATERIALS & INTERFACES
Volume 14, Issue 5, Pages 6442-6452

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsami.1c23708

Keywords

sepsis; toll-like receptor 2; siRNA; tetrahedral-framework nucleic acid; drug carrier; anti-inflammatory therapy

Funding

  1. National Key R&D Program of China [2019YFA0110600]
  2. National Natural Science Foundation of China [82171006, 81970986, 81771125]
  3. Postdoctoral Science Foundation of China [2020 T130443]

Ask authors/readers for more resources

Through using tFNA as carriers to deliver siRNA targeting downregulation of TLR2 expression for anti-inflammatory therapy, the study successfully reduced LPS-induced TLR2 elevation and decreased release of inflammatory factors, providing a new idea for the prevention and treatment of sepsis.
Sepsis is caused by the invasion of pathogenic microorganisms, which can lead to excessive expression of toll-like receptors (TLRs) in cells and uncontrollable amplification of the inflammatory response. TLR2, as an essential part of the TLR family, has a significant feature in the identification of innate immune responses. Therefore, blocking the expression and activation of TLR2 can inhibit the synthesis and release of inflammatory factors and avoid the occurrence of excessive inflammatory reactions. Small interfering RNA (siRNA) can selectively target the silencing or downregulation of pathogenic genes and has the advantages of high specificity, a strong effect, and fewer adverse reactions. However, the application of siRNA is limited by its high molecular weight, poor biostability, and difficulty in passive uptake into cells. Tetrahedral-framework nucleic acid (tFNA) is a new kind of three-dimensional nucleic acid nanomaterial, which has the advantages of good biocompatibility, stable structure, and editability. In this study, we used tFNA as carriers to deliver siRNA-targeting downregulation of TLR2 expression for anti-inflammatory therapy. We show that siRNA can specifically reduce lipopolysaccharide (LPS)-induced TLR2 elevation and reduce release of inflammatory factors in LPS-induced experimental sepsis, which provides a new idea for the prevention and treatment of sepsis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available